Alkermes

Alkermes is a global biopharmaceutical company focused on developing innovative medicines for diseases of the central nervous system (CNS) and addiction. The company was founded in 1987 and is headquartered in Dublin, Ireland, with its principal operations in Waltham, Massachusetts. Alkermes' research and development efforts are concentrated on creating novel small molecule drugs and biologics.

The company's portfolio includes treatments for conditions such as schizophrenia, bipolar I disorder, opioid dependence, and alcohol dependence. Alkermes is known for its work in developing medications that target specific neurotransmitter systems in the brain. They have brought several products to market that are used by patients worldwide.

Alkermes operates in a highly regulated industry and invests significantly in clinical trials to demonstrate the safety and efficacy of its drug candidates. The company collaborates with academic institutions and other pharmaceutical companies to advance its research and expand its pipeline. Alkermes aims to address unmet medical needs and improve the lives of patients suffering from challenging neurological and psychiatric disorders. Their business model involves both internal drug discovery and development as well as strategic acquisitions.